Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of Paxlovid for COVID-19:a meta-analysis
Qian Zheng, Pengfei Ma, Mingwei Wang, et al.
Journal of Infection (2022) Vol. 86, Iss. 1, pp. 66-117
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Seyed Mohammad Reza Hashemian, Amirhossein Sheida, Mohammad Taghizadieh, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114367-114367
Open Access | Times Cited: 90
Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: A rapid review and meta‐analysis
Behnam Amani, Bahman Amani
Journal of Medical Virology (2022) Vol. 95, Iss. 2
Open Access | Times Cited: 87
Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study
Guangtong Deng, Daishi Li, Yuming Sun, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Closed Access | Times Cited: 51
An overview on the treatments and prevention against COVID-19
Yunes Panahi, Armita Mahdavi Gorabi, Sona Talaei, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 48
Nirmatrelvir–ritonavir for the treatment of COVID‐19 patients: A systematic review and meta‐analysis
Huzaifa Ahmad Cheema, Uzair Jafar, Aruba Sohail, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 2
Closed Access | Times Cited: 41
Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19
Yuan Gao, Zujin Luo, Shan Ren, et al.
Journal of Infection (2023) Vol. 86, Iss. 6, pp. e158-e160
Open Access | Times Cited: 36
Nirmatrelvir–ritonavir compared with other antiviral drugs for the treatment of COVID‐19 patients: A systematic review and meta‐analysis
Fangyuan Tian, Zhaoyan Chen, Qiyi Feng
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Closed Access | Times Cited: 31
Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial
Jianchao Xu, Jinzhong Song, Ziyu Xie, et al.
Medicine (2023) Vol. 102, Iss. 51, pp. e36714-e36714
Open Access | Times Cited: 26
The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: A retrospective cohort study including 91,528 patients
Ting-Hui Liu, Jheng‐Yan Wu, Po‐Yu Huang, et al.
Journal of Infection (2023) Vol. 86, Iss. 3, pp. 256-308
Open Access | Times Cited: 24
Real-world effectiveness of Azvudine in hospitalized patients with COVID-19: a retrospective cohort study
Minxue Shen, Chenggen Xiao, Yuming Sun, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 18
Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines—A Scoping Review
Prabal Chourasia, Babu Sriram Maringanti, Morgan Edwards‐Fligner, et al.
Vaccines (2023) Vol. 11, Iss. 1, pp. 107-107
Open Access | Times Cited: 17
Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors
Wan‐Hsuan Hsu, Ya‐Wen Tsai, Jheng‐Yan Wu, et al.
Journal of Infection (2023) Vol. 86, Iss. 4, pp. e107-e110
Open Access | Times Cited: 17
Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID‐19: An updated meta‐analysis and trial sequential analysis
Haokun Tian, Changsen Yang, Tiangang Song, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 5
Closed Access | Times Cited: 17
Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna, et al.
Viruses (2024) Vol. 16, Iss. 1, pp. 112-112
Open Access | Times Cited: 5
Molecular basis for the activation ofPseudomonas aeruginosaMsbA by Zn2+
Jixing Lyu, Hanieh Bahramimoghaddam, Tianqi Zhang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
A multicenter, real-world cohort study: effectiveness and safety of Azvudine in hospitalized COVID-19 patients with pre-existing diabetes
Yongjian Zhou, Zecheng Yang, Shixi Zhang, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Efectividad y seguridad de nirmatrelvir + ritonavir en la Covid-19. Estudio NiRCoV
V M González-Rodríguez, M J Hernández-Arroyo, C Rodríguez-Barrueco, et al.
Medicina de Familia SEMERGEN (2025) Vol. 51, Iss. 6, pp. 102462-102462
Open Access
Effects of Nirmatrelvir/ritonavir (paxlovid) on the nervous system: analysis on adverse events released by FDA
Caixia Gao, Zhihui Liu, Zhen Zou, et al.
Expert Opinion on Drug Safety (2025), pp. 1-8
Closed Access
Drugs for COVID-19: An Update
Jessica Ceramella, Domenico Iacopetta, Maria Stefania Sinicropi, et al.
Molecules (2022) Vol. 27, Iss. 23, pp. 8562-8562
Open Access | Times Cited: 23
The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data
Vasileios Petrakis, Petros I. Rafailidis, Grigorios Trypsianis, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 976-976
Open Access | Times Cited: 14
Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada
Sara Carazo, Danuta M. Skowronski, Marc Brisson, et al.
The Lancet Healthy Longevity (2023) Vol. 4, Iss. 8, pp. e409-e420
Open Access | Times Cited: 13
SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
Alessandra Sacchi, Flavia Giannessi, Andrea Sabatini, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9353-9353
Open Access | Times Cited: 12
ACVPred: Enhanced prediction of anti-coronavirus peptides by transfer learning combined with data augmentation
Yi Xu, Tianyuan Liu, Yu Yang, et al.
Future Generation Computer Systems (2024) Vol. 160, pp. 305-315
Closed Access | Times Cited: 4
No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis
Huzaifa Ahmad Cheema, Arman Shafiee, Mohammad Mobin Teymouri Athar, et al.
Journal of Infection (2022) Vol. 86, Iss. 2, pp. 154-225
Open Access | Times Cited: 19
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era
Tingting Zhang, Weiwei Tian, Shuang Wei, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top